A detailed history of Goldman Sachs Group Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,358,534 shares of VRTX stock, worth $555 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
1,358,534
Previous 2,062,499 34.13%
Holding current value
$555 Million
Previous $967 Million 34.64%
% of portfolio
0.1%
Previous 0.17%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $324 Million - $356 Million
-703,965 Reduced 34.13%
1,358,534 $632 Million
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $260 Million - $321 Million
661,539 Added 47.22%
2,062,499 $967 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $34.2 Million - $37.5 Million
-83,974 Reduced 5.66%
1,400,960 $586 Million
Q4 2023

Feb 13, 2024

SELL
$343.0 - $410.68 $72.2 Million - $86.4 Million
-210,391 Reduced 12.41%
1,484,934 $604 Million
Q3 2023

May 14, 2024

BUY
$338.18 - $362.46 $71.2 Million - $76.3 Million
210,391 Added 14.17%
1,695,325 $590 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $40.8 Million - $43.7 Million
-120,547 Reduced 6.64%
1,695,325 $590 Million
Q2 2023

May 14, 2024

BUY
$314.42 - $351.91 $32.7 Million - $36.6 Million
104,141 Added 6.08%
1,815,872 $639 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $32.7 Million - $36.6 Million
104,141 Added 6.08%
1,815,872 $639 Million
Q1 2023

May 14, 2024

BUY
$283.23 - $323.1 $11.1 Million - $12.7 Million
39,358 Added 2.35%
1,711,731 $539 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $11.1 Million - $12.7 Million
39,358 Added 2.35%
1,711,731 $539 Million
Q4 2022

May 14, 2024

SELL
$285.76 - $321.48 $13.8 Million - $15.6 Million
-48,374 Reduced 2.81%
1,672,373 $483 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $13.8 Million - $15.6 Million
-48,374 Reduced 2.81%
1,672,373 $483 Million
Q3 2022

May 14, 2024

BUY
$273.83 - $305.53 $184 Million - $206 Million
673,107 Added 64.25%
1,720,747 $498 Million
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $184 Million - $206 Million
673,107 Added 64.25%
1,720,747 $498 Million
Q2 2022

May 14, 2024

SELL
$234.96 - $292.55 $103 Million - $128 Million
-437,294 Reduced 29.45%
1,047,640 $295 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $46.1 Million - $57.4 Million
-196,067 Reduced 15.76%
1,047,640 $295 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $12.5 Million - $14.7 Million
56,330 Added 4.74%
1,243,707 $325 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $36.5 Million - $46.1 Million
-206,385 Reduced 14.81%
1,187,377 $261 Million
Q3 2021

Nov 10, 2021

BUY
$181.39 - $202.99 $253 Million - $283 Million
1,393,762 New
1,393,762 $253 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.